II. Indications
- Moderate to severe acute pain in adults
III. Contraindications
- Severe hepatic Impairment (Child-Pugh Class C)
- Reduce dose in moderate hepatic Impairment
IV. Mechanism
- Non-Opioid Analgesic with unique mechanism, released in 2024 at $15/pill
-
Sodium Channel Blocker developed for use in acute pain
- Blocks transmission of Peripheral Nerve pain sesnsation
V. Dosing
- First Dose: 100 mg orally on an empty Stomach (except clear liquids)
- May be taken with clear liquids (water, apple juice, tea or black coffee)
- First dose should be taken >1 hour before or >2 hours after food
- Subsequent Doses: 50 mg orally every 12 hours
- May be taken with or without food
- May be used for up to 14 days (longer courses have not been studied)
VI. Adverse Effects
- Pruritus
- Rash
- Myalgias
- May be associated with increased Creatine Phosphokinase (CPK)
VII. Safety
- Avoid in pregnancy (unknown safety)
- Avoid in Lactation (present in animal milk, unknown safety)
VIII. Drug Interactions
-
CYP3A Inhibitors
- Avoid with use of strong CYP3A Inhibitors (e.g. Itraconazole)
- Avoid Grapefruit juice while on Suzetrigine
-
CYP3A Inducers
- Avoid with moderate to strong CYP3A Inducers (e.g. Rifampin)
-
Progestins (other than Levonorgestrel or Norethindrone)
- If used for Contraception, use an alternate contracepive while taking Suzetrigine and for 28 days after
IX. Efficacy
X. Resources
XI. References
- (2025) Presc Insights, Issue 3/2025
